|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPL35 |
Gene summary for RPL35 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPL35 | Gene ID | 11224 |
| Gene name | ribosomal protein L35 | |
| Gene Alias | DBA19 | |
| Cytomap | 9q33.3 | |
| Gene Type | protein-coding | GO ID | GO:0000463 | UniProtAcc | P42766 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11224 | RPL35 | GSM4909282 | Human | Breast | IDC | 1.47e-23 | -1.80e-01 | -0.0288 |
| 11224 | RPL35 | GSM4909285 | Human | Breast | IDC | 5.84e-04 | -6.57e-02 | 0.21 |
| 11224 | RPL35 | GSM4909287 | Human | Breast | IDC | 2.31e-20 | -3.40e-01 | 0.2057 |
| 11224 | RPL35 | GSM4909291 | Human | Breast | IDC | 7.54e-05 | 1.24e-01 | 0.1753 |
| 11224 | RPL35 | GSM4909293 | Human | Breast | IDC | 1.58e-12 | -9.55e-02 | 0.1581 |
| 11224 | RPL35 | GSM4909294 | Human | Breast | IDC | 5.34e-17 | 1.94e-01 | 0.2022 |
| 11224 | RPL35 | GSM4909295 | Human | Breast | IDC | 6.48e-05 | 1.27e-01 | 0.0898 |
| 11224 | RPL35 | GSM4909296 | Human | Breast | IDC | 1.14e-05 | 1.25e-01 | 0.1524 |
| 11224 | RPL35 | GSM4909297 | Human | Breast | IDC | 6.42e-03 | -1.56e-01 | 0.1517 |
| 11224 | RPL35 | GSM4909298 | Human | Breast | IDC | 3.49e-16 | -1.41e-01 | 0.1551 |
| 11224 | RPL35 | GSM4909304 | Human | Breast | IDC | 2.36e-15 | -1.28e-01 | 0.1636 |
| 11224 | RPL35 | GSM4909306 | Human | Breast | IDC | 4.00e-09 | -1.02e-01 | 0.1564 |
| 11224 | RPL35 | GSM4909307 | Human | Breast | IDC | 1.11e-04 | -9.49e-02 | 0.1569 |
| 11224 | RPL35 | GSM4909308 | Human | Breast | IDC | 2.01e-13 | -1.99e-01 | 0.158 |
| 11224 | RPL35 | GSM4909311 | Human | Breast | IDC | 5.31e-20 | 9.63e-02 | 0.1534 |
| 11224 | RPL35 | GSM4909315 | Human | Breast | IDC | 5.92e-24 | -2.95e-01 | 0.21 |
| 11224 | RPL35 | GSM4909316 | Human | Breast | IDC | 4.24e-17 | -6.18e-01 | 0.21 |
| 11224 | RPL35 | GSM4909317 | Human | Breast | IDC | 7.71e-14 | -2.32e-01 | 0.1355 |
| 11224 | RPL35 | GSM4909319 | Human | Breast | IDC | 4.11e-51 | -8.24e-01 | 0.1563 |
| 11224 | RPL35 | GSM4909321 | Human | Breast | IDC | 5.00e-08 | -1.60e-01 | 0.1559 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
| GO:00226139 | Breast | Precancer | ribonucleoprotein complex biogenesis | 79/1080 | 463/18723 | 2.11e-18 | 1.03e-15 | 79 |
| GO:00422549 | Breast | Precancer | ribosome biogenesis | 52/1080 | 299/18723 | 7.35e-13 | 1.51e-10 | 52 |
| GO:00422739 | Breast | Precancer | ribosomal large subunit biogenesis | 22/1080 | 72/18723 | 5.03e-11 | 5.61e-09 | 22 |
| GO:00063646 | Breast | Precancer | rRNA processing | 35/1080 | 225/18723 | 7.90e-08 | 4.60e-06 | 35 |
| GO:00160726 | Breast | Precancer | rRNA metabolic process | 36/1080 | 236/18723 | 8.59e-08 | 4.84e-06 | 36 |
| GO:00344705 | Breast | Precancer | ncRNA processing | 42/1080 | 395/18723 | 9.91e-05 | 1.83e-03 | 42 |
| GO:00004703 | Breast | Precancer | maturation of LSU-rRNA | 7/1080 | 28/18723 | 8.46e-04 | 9.82e-03 | 7 |
| GO:00346604 | Breast | Precancer | ncRNA metabolic process | 45/1080 | 485/18723 | 1.15e-03 | 1.26e-02 | 45 |
| GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
| GO:002261314 | Breast | IDC | ribonucleoprotein complex biogenesis | 83/1434 | 463/18723 | 2.01e-13 | 5.20e-11 | 83 |
| GO:004227314 | Breast | IDC | ribosomal large subunit biogenesis | 22/1434 | 72/18723 | 1.04e-08 | 7.67e-07 | 22 |
| GO:004225414 | Breast | IDC | ribosome biogenesis | 52/1434 | 299/18723 | 1.90e-08 | 1.32e-06 | 52 |
| GO:000636414 | Breast | IDC | rRNA processing | 35/1434 | 225/18723 | 4.59e-05 | 1.03e-03 | 35 |
| GO:001607214 | Breast | IDC | rRNA metabolic process | 36/1434 | 236/18723 | 5.48e-05 | 1.17e-03 | 36 |
| GO:000047012 | Breast | IDC | maturation of LSU-rRNA | 7/1434 | 28/18723 | 4.31e-03 | 3.35e-02 | 7 |
| GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
| GO:002261324 | Breast | DCIS | ribonucleoprotein complex biogenesis | 83/1390 | 463/18723 | 3.65e-14 | 1.09e-11 | 83 |
| GO:004227324 | Breast | DCIS | ribosomal large subunit biogenesis | 22/1390 | 72/18723 | 5.88e-09 | 4.82e-07 | 22 |
| GO:004225423 | Breast | DCIS | ribosome biogenesis | 52/1390 | 299/18723 | 6.73e-09 | 5.44e-07 | 52 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0517145 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
| hsa0301045 | Cervix | N_HPV | Ribosome | 39/349 | 167/8465 | 2.05e-19 | 2.79e-17 | 2.18e-17 | 39 |
| hsa0517155 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
| hsa0301055 | Cervix | N_HPV | Ribosome | 39/349 | 167/8465 | 2.05e-19 | 2.79e-17 | 2.18e-17 | 39 |
| hsa03010 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
| hsa030101 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
| hsa030102 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa051712 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
| hsa030103 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa051713 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
| hsa030104 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
| hsa051714 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
| hsa030105 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
| hsa051715 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
| hsa030106 | Colorectum | MSI-H | Ribosome | 87/797 | 167/8465 | 5.55e-46 | 1.80e-43 | 1.51e-43 | 87 |
| hsa051716 | Colorectum | MSI-H | Coronavirus disease - COVID-19 | 91/797 | 232/8465 | 2.21e-35 | 3.58e-33 | 3.00e-33 | 91 |
| hsa030107 | Colorectum | MSI-H | Ribosome | 87/797 | 167/8465 | 5.55e-46 | 1.80e-43 | 1.51e-43 | 87 |
| hsa051717 | Colorectum | MSI-H | Coronavirus disease - COVID-19 | 91/797 | 232/8465 | 2.21e-35 | 3.58e-33 | 3.00e-33 | 91 |
| Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPL35 | SNV | Missense_Mutation | c.359C>G | p.Ala120Gly | p.A120G | P42766 | protein_coding | deleterious(0) | possibly_damaging(0.85) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| RPL35 | SNV | Missense_Mutation | c.237N>C | p.Lys79Asn | p.K79N | P42766 | protein_coding | tolerated(0.23) | possibly_damaging(0.823) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RPL35 | SNV | Missense_Mutation | rs771742167 | c.143G>A | p.Arg48Gln | p.R48Q | P42766 | protein_coding | tolerated(0.09) | benign(0.097) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| RPL35 | SNV | Missense_Mutation | rs541571516 | c.251G>A | p.Arg84Gln | p.R84Q | P42766 | protein_coding | tolerated(0.06) | benign(0.295) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| RPL35 | SNV | Missense_Mutation | novel | c.172C>T | p.Leu58Phe | p.L58F | P42766 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| RPL35 | SNV | Missense_Mutation | rs753607321 | c.350G>A | p.Arg117Gln | p.R117Q | P42766 | protein_coding | deleterious(0.04) | probably_damaging(0.966) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPL35 | SNV | Missense_Mutation | rs541571516 | c.251G>A | p.Arg84Gln | p.R84Q | P42766 | protein_coding | tolerated(0.06) | benign(0.295) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPL35 | SNV | Missense_Mutation | novel | c.274N>T | p.Arg92Cys | p.R92C | P42766 | protein_coding | tolerated(0.06) | benign(0.082) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RPL35 | SNV | Missense_Mutation | novel | c.274N>T | p.Arg92Cys | p.R92C | P42766 | protein_coding | tolerated(0.06) | benign(0.082) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL35 | SNV | Missense_Mutation | novel | c.212N>G | p.Lys71Arg | p.K71R | P42766 | protein_coding | deleterious(0.04) | probably_damaging(0.946) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |